Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Palo Alto Investors LP

Q3 2024 · 13F-HR

Palo Alto Investors LPholdings as filed

Filed 2024-11-14 · accession 0001306923-24-000012

$769.9M
Reported value
45
Positions
2024-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
457669307INSMINSMED INC$141.7M18.4%1,940,993CommonSOLE
03152W109AM6AMICUS THERAPEUTICS INC$87.0M11.3%8,145,311CommonSOLE
09061G101BMRNBIOMARIN PHARMACEUTICAL INC$76.6M9.95%1,090,056CommonSOLE
91307C102UTHRUNITED THERAPEUTICS CORP$65.7M8.53%183,246CommonSOLE
09062X103BIIBBIOGEN INC$44.4M5.76%228,916CommonSOLE
852312305STAASTAAR SURGICAL CO$40.6M5.27%1,091,608CommonSOLE
004225108ACADACADIA PHARMACEUTICALS INC$38.8M5.04%2,523,956CommonSOLE
02043Q107ALNYALNYLAM PHARMACEUTICALS INC$38.7M5.03%140,681CommonSOLE
G72800108PRTAPROTHENA CORP PLC$29.1M3.78%1,737,964CommonSOLE
462260100IOVAIOVANCE BIOTHERAPEUTICS INC$28.6M3.71%3,041,685CommonSOLE
032724106ANABANAPTYSBIO INC$28.3M3.67%843,971CommonSOLE
803607100SRPTSAREPTA THERAPEUTICS INC$26.3M3.41%210,258CommonSOLE
G01767105ALKSALKERMES PLC$10.8M1.40%384,656CommonSOLE
69366J200PTCTPTC THERAPEUTICS INC$9.8M1.27%264,469CommonSOLE
016255101ALGNALIGN TECHNOLOGY INC$9.6M1.25%37,772CommonSOLE
28238P109EHTHEHEALTH INC$9.6M1.24%2,347,519CommonSOLE
G6674U108NVCRNOVOCURE LTD$9.3M1.21%593,540CommonSOLE
00445A100ACELYRIN INC$8.8M1.15%1,792,895CommonSOLE
761330109RVNCEURREVANCE THERAPEUTICS INC$8.4M1.09%1,611,787CommonSOLE
87164F105SNDXSYNDAX PHARMACEUTICALS INC$7.8M1.01%405,193CommonSOLE
78667J108SG7SAGE THERAPEUTICS INC$7.3M0.95%1,010,833CommonSOLE
38341P102GOSSGOSSAMER BIO INC$6.2M0.80%6,277,093CommonSOLE
48576U106KPTIEURKARYOPHARM THERAPEUTICS INC$4.2M0.55%5,102,193CommonSOLE
64157F103NVROEURNEVRO CORP$4.2M0.54%750,371CommonSOLE
09075V102BNTXBIONTECH SE-ADR$3.0M0.39%25,206CommonSOLE
92539P101VERVE THERAPEUTICS INC$2.8M0.36%575,817CommonSOLE
28176E108EWEDWARDS LIFESCIENCES CORP$2.6M0.34%39,473CommonSOLE
604749101MIRMMIRUM PHARMACEUTICALS INC$2.5M0.33%64,700CommonSOLE
75955J402RLMDRELMADA THERAPEUTICS INC$2.4M0.31%732,400CommonSOLE
67080N101NUVBNUVATION BIO INC$1.8M0.23%772,652CommonSOLE
877619106TSHATAYSHA GENE THERAPIES INC$1.6M0.21%811,268CommonSOLE
89422G107TVTXTRAVERE THERAPEUTICS INC$1.5M0.20%110,719CommonSOLE
86150R107STOKSTOKE THERAPEUTICS INC$1.5M0.20%125,861CommonSOLE
088786108BCYCBICYCLE THERAPEUTICS PLC-ADR$1.3M0.18%59,582CommonSOLE
444859102HUMHUMANA INC$1.3M0.16%3,985CommonSOLE
01438T106ALDXALDEYRA THERAPEUTICS INC$1.2M0.16%225,465CommonSOLE
92941V308VYNEVYNE THERAPEUTICS INC PIPE$837,4160.11%445,434CommonSOLE
28623U101ELEVATION ONCOLOGY INC$778,7280.10%1,298,097CommonSOLE
45783C200TILINSTIL BIO INC$751,6280.10%11,165CommonSOLE
00461U105ACRSACLARIS THERAPEUTICS INC$655,3070.09%569,832CommonSOLE
747324101PYXSPYXIS ONCOLOGY INC$623,9000.08%170,000CommonSOLE
37148K100GBIOGBXGENERATION BIO CO$371,6730.05%150,475CommonSOLE
09609G100BLUEBIRD BIO INC$313,9130.04%604,260CommonSOLE
M96088105URGNUROGEN PHARMA LTD$311,1500.04%24,500CommonSOLE
00289Y206ABEOABEONA THERAPEUTICS INC$81,3070.01%12,865CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.